FDA Hormone Therapy Education Campaign Affirms Osteoporosis Use
This article was originally published in The Tan Sheet
FDA is not taking a position on the combination of "natural" products used in conjunction with hormone therapy in its consumer education campaign on hormone therapy launched Sept. 9
You may also be interested in...
FDA expects to complete reviews of competitive outsourcing opportunities for certain accounting and clerical services by the end of fiscal year 2004
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning